Prescribing chemotherapy can be considered a core competency or a privilege, depending on where an oncology nurse practitioner (NP) practices. States employ any of 3 models for the role of NPs, with varying levels of independence granted. A discussion on the role of advanced NPs in prescribing oncologic therapies was the focus of an oral presentation at the 46th Annual Oncology Nursing Society (ONS) Congress.

The trajectory of NP licensure in the US has risen rapidly over the years, explained Kim Noonan, DNP, ANP-BC, AOCN, of Dana Farber Cancer Institute in Boston, Massachusetts. However, NPs today are experiencing difficulty with finding mentorship and with finding clinical placements, especially given COVID. “We really are almost at a crisis with this,” noted Dr Noonan.

Although laws vary from state to state, some have established requirements that allow NPs to prescribe chemotherapy, and the American Society of Clinical Oncology and Oncology Nursing Society provides safety standards. These requirements include obtaining sufficient education, demonstrating an ability to perform dose calculations, and ordering cancer therapy under the supervision of another provider a minimum number of times.


Continue Reading

The most important qualities for ordering cancer therapy are knowledge of the type of cancer, cancer therapies in general, the therapy being prescribed, and how to order the therapy in the electronic medical record system, explained Suzanne McGettigan, MSN, ANP-BC, AOCN, of the University of Pennsylvania Abramson Cancer Center in Philadelphia, Pennsylvania. An advanced NP can be the prescriber, monitor for toxicities, and complete documentation.

Ordering cancer therapy is complex and there are many factors for the NP to consider, including state laws and institutional policies. “Oncology NPs are educated, trained, and experienced, and can play a very essential part of the therapy plan for patients with cancer,” concluded Ms McGettigan.

Disclosure: One study author declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original video for a full list of authors’ disclosures.

Reference

Rodgers Noonan K, McGettigan S. The role of the APRN in prescribing oncologic agents. Oral presentation at: 46th Annual ONS Congress; April 20-29, 2021. Accessed April 30, 2021.

This article originally appeared on Oncology Nurse Advisor